Pancreatic Cancer Research

ResearcherWakayama Medical UniversityActive in the last 2 years

Yuki Kawaji

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8179-2641; OpenAlex author ID A5074024438. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2020: 2 papers · 2021: 3 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 3 papers

Papers 13

  1. Comparison of Nanoliposomal Irinotecan Plus Fluorouracil/Leucovorin and S-1, Irinotecan, and Oxaliplatin as Second-Line Chemotherapy After Gemcitabine Plus Nab… Co-author DOI 10.1002/jhbp.70122↗
  2. Reply to "Prognostic value of functional assessment in sarcopenia among pancreatic cancer patients". Co-author DOI 10.1007/s00535-026-02446-w↗
  3. Contrast-enhanced harmonic endoscopic ultrasonography (EUS)-guided tissue acquisition significantly improves diagnostic yield for small liver metastases derive… Co-author DOI 10.1016/j.pan.2025.12.001↗
  4. Impact of sarcopenia and changes in skeletal muscle mass on prognosis of patients with pancreatic ductal adenocarcinoma receiving chemotherapy with first-line … Co-author DOI 10.1007/s00535-025-02283-3↗
  5. Utility of contrast-enhanced harmonic endoscopic ultrasonography for prediction of pathological response after neoadjuvant chemotherapy in patients with pancre… Co-author DOI 10.1016/j.pan.2023.10.016↗
  6. Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gem… Co-author DOI 10.1016/j.pan.2021.12.013↗
  7. Contrast-enhanced harmonic endoscopic ultrasonography for predicting the efficacy of first-line gemcitabine and nab-paclitaxel chemotherapy in pancreatic cance… Co-author DOI 10.1016/j.pan.2022.04.005↗
  8. Kras Gene Analysis Using Liquid-Based Cytology Specimens Predicts Therapeutic Responses and Prognosis in Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers14030551↗
  9. Computed tomography findings for predicting the future occurrence of pancreatic cancer: value of pancreatic volumetry. Co-author DOI 10.1007/s10147-021-01915-x↗
  10. Covered self-expandable metal stents versus plastic stents for preoperative biliary drainage in patient receiving neo-adjuvant chemotherapy for borderline rese… Co-author DOI 10.1111/den.13926↗
  11. Value of contrast-enhanced harmonic endoscopic ultrasound for diagnosing hepatic metastases of pancreatic cancer: A prospective study. Co-author DOI 10.1111/jgh.15661↗
  12. Fully covered self-expandable metal stent with an anti-migration system vs plastic stent for distal biliary obstruction caused by borderline resectable pancrea… Co-author DOI 10.1097/md.0000000000018718↗
  13. Utility of Contrast-Enhanced Harmonic Endoscopic Ultrasonography for Early Diagnosis of Small Pancreatic Cancer. Co-author DOI 10.3390/diagnostics10010023↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masahiro Itonaga · 13 shared papers, 2020–2026 · strength 2.20
  2. Takashi Tamura · 13 shared papers, 2020–2026 · strength 2.20
  3. Yasunobu Yamashita · 13 shared papers, 2020–2026 · strength 2.20
  4. Masayuki Kitano · 13 shared papers, 2020–2026 · strength 2.20
  5. Reiko Ashida · 11 shared papers, 2021–2026 · strength 2.01
  6. Tomoya Emori · 9 shared papers, 2021–2026 · strength 1.56
  7. Keiichi Hatamaru · 9 shared papers, 2020–2023 · strength 1.09
  8. Manabu Kawai · 9 shared papers, 2020–2023 · strength 1.09
  9. Hiroki Yamaue · 4 shared papers, 2020–2022 · strength 0.42
  10. Ken‐ichi Okada · 3 shared papers, 2020–2021 · strength 0.30
  11. Seiko Hirono · 3 shared papers, 2020–2021 · strength 0.30
  12. Yuji Kitahata · 2 shared papers, 2020–2021 · strength 0.21
  13. Motoki Miyazawa · 2 shared papers, 2020–2021 · strength 0.21
  14. Ken‐ichi Okada · 1 shared paper, 2023 · strength 0.17
  15. Takeichi Yoshida · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.